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Abstract 
A DNA vaccine, pCAG-HAk, expressing the full-length haemagglutinin (HA) gene of avian influenza A/Eurasian coot/Western 
Australia/2727/1979 (H6N2) virus, together with a Kozak sequence, in a pCAGGS vector was formulated with a novel nanoparticle, 
Phema. Two intramuscular immunizations of layer chickens at 3-week intervals with different doses of a nano-vaccine as well as 100µg 
pCAG-HAk failed to induce detectable haemagglutination-inhibition (HI) antibody. Following virus challenge, the pCAG-HAk 
vaccinated group did not show a statistically significant difference in frequency of virus shedding in both oropharyngeal and cloacal 
swabs from the naive control group. However, in comparison with the naive control group, the 100µg nano-vaccine group did 
significantly reduce virus shedding from the oropharynx. Despite lack of a dose-sparing effect from the nano-vaccine, there was a dose-
response effect. This pilot study indicated that Phema used as an adjuvant augmented the immune response induced by the pCAG-HAk
construct.
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1. Introduction 
Genetic immunization is well documented to induce protective immunity to various infectious and non-infectious 
diseases in a range of animals (1). However, rapid degradation and poor cellular uptake of plasmid DNA has significantly 
impacted on the efficacy of 'naked' plasmid DNA vaccines (27). As adjuvants have historically played a major role in 
successful vaccine development (22), some chemical adjuvants such as Bupivacaine (26) or Marcaine, Ubenimex (19), 
monophosphoryl lipid A (MPL) (20), QS-21 saponin (21), levamisole(11)  have been explored and have showed 
respectable facilitating effect on immune responses to DNA vaccines. Further investigation of novel adjuvants and their 
formulation technologies could improve the utility of plasmid DNA vaccination. 
Nano-particles, varying in size from 10 to 500 nm, are solid particles made from inert materials (2).  They are potentially 
biocompatible and biodegradable, are relatively stable in vivo, are relatively easy to link with immunogens, have 
straightforward delivery methods and show little or no side effects (3, 23). As early as 1995, solid inert beads adsorbed with 
antigen were reported to prime CD8+T cell responses (7). Inert nanoparticles have subsequently been shown to induce 
strong immune responses to protein and peptide antigens in mice (8, 9), sheep (22), pigs (2) and cattle (2). In the context of 
DNA vaccines, a cationic nanoparticle formulated plasmid DNA encoding a reporter gene enhanced in vitro cell 
transfection efficiency and elicited 16-200-fold greater immune responses in mice than naked plasmid DNA alone 
following multiple delivery routes (3, 4, 5, 6). Co-administration of cholera toxin and lipid A with a nanoparticle-based 
plasmid DNA showed a synergistic effect and hence further enhanced immune responses (6). Thus, nanoparticles, as a 
novel class of adjuvants, have the potential to induce immune responses to protein or plasmid DNA immunogens without 
the side effects typically associated with local tissue damage caused by conventional chemical adjuvants. Though the 
microparticle formulated plasmid DNA encoding the NP gene of A/PR/8/34 (H1N1) virus was shown to enhance immune 
response in mice (10), there has been no reports on nanoparticle-based avian influenza DNA vaccines in chickens.
© 2010 Published by Elsevier Ltd.
3rd  Vaccine Global Congress, Singapore 2009 
Songhua Shan et al. / Procedia in Vaccinology 2 (2010) 40–43 41
For Australian biosecurity reasons, a low pathogenic avian influenza (LPAI) virus, A/Eurasian coot/Western 
Australia/2727/1979 (H6N2), isolated from a healthy Eurasian coot (Fulica atra) in Australia, was selected to perform 
this DNA vaccine adjuvant study. In the present study we investigated the immunologic adjuvant effect of a novel self-
prepared Phema for DNA vaccination against avian influenza.
2. Formulation of plasmid DNA with Phema 
The pCAG-HAk plasmid DNA expressing the complete haemagglutinin (HA) gene of avian influenza A/Eurasian 
coot/Western Australia/2727/1979 (H6N2) virus, together with a Kozak sequence, in a pCAGGS vector was used for a 
DNA vaccine as described previously (24).
A novel polymer (2-hydroxyethyl-methacrylate) (Phema), which formed a 150-300 nm hydrophilic nanoparticle 
suspension, was provided by the Nanotechnology Group, Murdoch University, Australia. Optimization of the solvent for 
mixing the Phema and DNA was determined using 100% dH2O, dH2O/ethanol (50:50) and 100% ethanol and calculation of 
the level of DNA binding. Then 2 mL of 1% Phema (w/v in ethanol) was sonicated for a few seconds followed by the 
addition of 1 mL of 1% polyvinyl alcohol (PVA) (w/v in dH2O) and sonication for 1 min on ice. Subsequently 200 µL of 
plasmid DNA (9.3 µg/µL) was added and sonicated for 2 min on ice. The resultant solution was filtered through a 0.2 µm 
membrane to remove the surfactant. The flow-through was centrifuged at 15,000 g for 20 min at room temperature. The 
pellet was dissolved in PBS and the amount of DNA coated with nano-beads was calculated by subtracting the amount of 
DNA in the supernatant, measured by a Nanodrop spectrophotometer (Thermo Scientific, MA, USA), from the total DNA 
added.
3. Vaccination regime
Three-week old Hy-Line chickens (free of avian influenza) were housed in free-range pens with access to water and feed 
ad libitum. The experimental protocol used was shown in Table 8.1. Birds intramuscularly received two 0.2 mL injections 
(0.1 mL per leg) at 3 week intervals with 200 µL PBS (control), 100 µg pCAG-HAk, 10 µg, 100 µg, 200 µg  Phema-
adjuvanted pCAG-HAk. Sera were weekly collected to detect H6-specific antibody by haemagglutination-inhibition (HI) 
(16, 24).
Three weeks following the booster vaccination, each chicken received 0.5 mL H6N2 virus (106.5 EID50 /0.1 mL) by nasal 
instillation (0.1 mL), eyedrop (0.1 mL) and oral route (0.3 mL). Following challenge, in addition to daily observing all
chickens, oropharyngeal or cloacal swabs were collected every second day over a seven day period. Virus isolation was 
performed as described (16). 
4. Results and Discussion 
Experiments with different ratios of alcohol and water showed that Phema adjuvant prepared with 100% ethanol as 
solvent gave the highest DNA binding rate. Thus, 100% alcohol was used for the preparation of the Phema adjuvant 
vaccine. Subsequently, the maximal plasmid DNA-Phema binding rate, determined using a constant Phema concentration 
and different DNA concentrations, was approximately 30%. 
No H6 HI antibody titre was detected in all Hy-Line chickens following two immunizations. By 10 days post virus 
challenge, all birds sero-converted with significant difference in the geometric mean titre (GMT) of HI antibody between 
pre- and post-challenge using the paired-sample T test (Table 1).  
Table 1. Antibody response prior to and post virus challenge.
Phema 
Naïve control pCAG-HAk 
200 µg 100 µg 10 µg 
Pre-challenge 0 0 0 0 0 
Post-challenge 6.0±2.0* 5.6±1.7 5.3±1.5 5.3±1.5 6.6±2.1 
* Values represent geometric mean titre (GMT)± SD of each group  (exponent index in log 2).  
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As shown in Table 2, in comparison with the naive control group, the pCAG-HAk vaccinated group reduced the virus 
excretion rate from 70.8% to 45% via oropharynx post challenge and from 12.5% to 0 via cloaca. However, the pCAG-
HAk vaccinated group was not significantly different from the naive control group in oropharyngeal and cloacal swabs. 
Possibly, the pCAG-HAk vaccine may have elicited some borderline level of protective immunity in the oropharynx (Chi 
square, P= 0.083).
In comparison with the naive control group, the 100µg Phema adjuvanted pCAG-HAk group showed significant 
decrease (Fisher’s exact test, P=0.014) in virus shedding in oropharyngeal swabs but no significant difference in cloacal 
swabs. This suggested that Phema as adjuvant further augmented the immune response induced by the pCAG-HAk 
construct.
Table 2. Level of virus shedding in oropharyngeal and cloacal swabs in vaccinated chickens following H6N2 avian influenza virus challenge. 
Phema 
Naïve control pCAG-HAk 
200 µg 100 µg 10 µg 
Oropharyngeal swabs 17/24 (70.8)* a 9/20 (45) ab 8/16 (50) ab 3/12 (25) bc 9/20 (45) ab
Cloacal swabs 3/24 (12.5) 0/20 (0) 1/16 (6.3) 0/12 (0) 1/20 (5)
* Number of swabs positive for virus isolation/total number of swabs tested. Percentage rate is shown in parentheses.   
For the oropharyngeal swab row, different lowercase superscript letters indicate statistical differences (P < 0.05) within 
the row using Chi square or Fisher’s exact test. There were no significant differences between groups for the cloacal swabs. 
The use of particulate carriers as novel vaccine delivery systems is an area currently receiving a high level of interest. 
Micro- and nano-size particle characteristics, such as size and surface properties, including surface charge and 
hydrophobicity, affect vaccine efficacy (28). A range of inert nanoparticles have been tested and shown to be effective 
Due to the hydrophilicity of Phema, it is suspected that the ethanol solvent used in the current study may have imparted 
positive surface charges and allowed more absorption of the plasmid DNA than with water as a solvent. Plasmid DNA was 
possibly absorbed to the surface of Phema through electrostatic interaction or covalent binding and this did not appear to 
damage the DNA’s biological functions. The interaction also appeared to be complex because the optimum effect was 
achieved with the 100µg dose group and the response was poorer with both the 10 and 200µg dose groups. The 
mechanisms behind the observed adjuvant effect have not yet been resolved. Possible mechanisms are that these 
nanocarriers prevent DNA degradation and facilitate targeted delivery to antigen presenting cells (12, 25). 
The pCAG-HAk vaccines with or without adjuvants did not induce a measurable antibody response in the Hy-Line 
chickens, however, the Phema adjuvanted pCAG-HAk vaccines gave some enhanced reduction in virus shedding from the 
oropharynx. The reason why the pCAG-HAk induced antibody responses in SPF chickens (24), but lack of antibody 
response in Hy-Line chickens will require further investigation.
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delivery vehicles for protein and peptide antigens (3, 4, 5, 6, 12, 13, 14). Nevertheless, application of nanoparticles with
DNA vaccines is only at the exploratory stage (6, 15). A biodegradable copolymer Phema has also been used in
a drug delivery system (17, 18). However, there appears to be no previous reports using Phema for vaccine adjuvant 
purposes.
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